



CENTER FOR MEDICARE

DATE: April 20, 2023

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE Organizations

FROM: Amy Larrick Chavez-Valdez
Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: **CORRECTION** - Contract Year 2023 Part D Drug Management Program Guidance

This memorandum provides updated information to Part D sponsors regarding contract year (CY) 2023 Drug Management Programs (DMPs).

Following is a summary of changes compared to the November 28, 2022 memorandum, *Contract Year 2023 Part D Drug Management Program Guidance*. New and revised text in the attached guidance is shown in red, italicized font.

- Throughout: Edits made to clarify existing policy.
- Sections 8.1, 8.2.1, 8.2.2, and 8.4: Clarified guidance to notify a beneficiary of a DMP exemption after Initial Notice and Second Notice.
- Section 11.2: Updated information for MARx reporting.

Additional resources and guidance available on the [CMS Part D Overutilization website](#) include:

- CY 2023 Overutilization Monitoring System (OMS) technical guidance. CMS will incorporate the revised opioid morphine milligram equivalent (MME) conversion factors from the [CDC Clinical Practice Guideline for Prescribing Opioids for Pain](#) in the April 2023 and July 2023 OMS reports. An updated OMS User Guide will be available at that time.
- Standardized beneficiary notices, model prescriber inquiry letter, and model transfer memo associated with PRA package CMS-10141 (OMB Control No. 0938-0964).
- Model Part D Drug Management Program Retraction Notice for Exempted Beneficiaries after Initial Notice.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.

Further information about appeals of at-risk determinations can be found in the Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals Guidance posted here:

<https://www.cms.gov/Medicare/Appeals-and-Grievances/MMCAG/Downloads/Parts-C-and-D-Enrollee-Grievances-Organization-Coverage-Determinations-and-Appeals-Guidance.pdf>

Questions about DMPs may be submitted to PartD_OM@cms.hhs.gov.